High-dose chemotherapy with autologous stem cell support for first-line treatment of aggressive non-Hodgkin lymphoma: a systematic review and meta-analysis based on individual patient data-Reference-Cited by-同舟云学术

High-dose chemotherapy with autologous stem cell support for first-line treatment of aggressive non-Hodgkin lymphoma: a systematic review and meta-analysis based on individual patient data

Published:2016-12-08 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Brillant Corinne¹,Skoetz Nicole¹,Kluge Sabine²,Schwarzer Guido³,Trelle Sven⁴,Greb Alexander¹,Schulz Holger¹,Engert Andreas⁵,Bohlius Julia⁴

Affiliation:

1. University Hospital of Cologne; Cochrane Haematological Malignancies Group, Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924

2. Burbacher Straße 116 Bonn Germany 53129

3. Medical Center - University of Freiburg; Center for Medical Biometry and Medical Informatics; Stefan-Meier-Str. 26 Freiburg Germany D-79104

4. University of Bern; Institute of Social and Preventive Medicine; Finkenhubelweg 11 Bern Switzerland CH-3012

5. University Hospital of Cologne; Department I of Internal Medicine; Kerpener Str. 62 Cologne Germany 50924

Publisher

Wiley

Subject

Pharmacology (medical)

Reference48 articles.

1. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling;Alizadeh;Nature,2000

2. Revised Response Criteria for Malignant Lymphoma;Cheson;Journal of Clinical Oncology,2007

3. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study;Coiffier;Blood,1998

4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;New England Journal of Medicine,2002

5. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group;Cooper;Journal of Clinical Oncology,1994